vs
Side-by-side financial comparison of Autolus Therapeutics plc (AUTL) and BGSF, INC. (BGSF). Click either name above to swap in a different company.
BGSF, INC. is the larger business by last-quarter revenue ($22.0M vs $21.2M, roughly 1.0× Autolus Therapeutics plc). BGSF, INC. runs the higher net margin — -5.3% vs -373.3%, a 368.0% gap on every dollar of revenue. BGSF, INC. produced more free cash flow last quarter ($1.7M vs $-72.3M).
Autolus Therapeutics plc is a clinical-stage biopharmaceutical company specializing in the development of next-generation engineered chimeric antigen receptor T-cell (CAR-T) therapies for the treatment of hematological malignancies and solid tumors. It operates in the global oncology biotech market, advancing a pipeline of targeted immunotherapy candidates across multiple clinical development stages.
BGSF Inc. is a leading U.S.-headquartered workforce solutions firm that provides tailored staffing, talent recruitment, and end-to-end workforce management services. It serves core segments including information technology, healthcare, professional administration, light industrial, and creative industries, catering to small, mid-sized and large enterprise clients across North America.
AUTL vs BGSF — Head-to-Head
Income Statement — Q3 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $21.2M | $22.0M |
| Net Profit | $-79.1M | $-1.2M |
| Gross Margin | — | 35.0% |
| Operating Margin | -337.9% | -17.6% |
| Net Margin | -373.3% | -5.3% |
| Revenue YoY | — | -9.4% |
| Net Profit YoY | 3.6% | -18.2% |
| EPS (diluted) | $-0.30 | $-0.12 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $22.0M | ||
| Q3 25 | $21.2M | $26.9M | ||
| Q2 25 | $20.9M | $23.5M | ||
| Q1 25 | $9.0M | $20.9M | ||
| Q4 24 | — | $24.3M | ||
| Q3 24 | $0 | $29.8M | ||
| Q2 24 | $0 | $25.7M | ||
| Q1 24 | $10.1M | $24.5M |
| Q4 25 | — | $-1.2M | ||
| Q3 25 | $-79.1M | $-5.8M | ||
| Q2 25 | $-47.9M | $-3.7M | ||
| Q1 25 | $-70.2M | $-722.0K | ||
| Q4 24 | — | $-981.0K | ||
| Q3 24 | $-82.1M | $-804.0K | ||
| Q2 24 | $-58.3M | $-761.0K | ||
| Q1 24 | $-52.7M | $-792.0K |
| Q4 25 | — | 35.0% | ||
| Q3 25 | — | 35.9% | ||
| Q2 25 | — | 35.8% | ||
| Q1 25 | — | 36.2% | ||
| Q4 24 | — | 35.9% | ||
| Q3 24 | — | 35.9% | ||
| Q2 24 | — | 37.3% | ||
| Q1 24 | — | 38.1% |
| Q4 25 | — | -17.6% | ||
| Q3 25 | -337.9% | -3.5% | ||
| Q2 25 | -292.6% | -18.8% | ||
| Q1 25 | -726.3% | 1.6% | ||
| Q4 24 | — | -15.7% | ||
| Q3 24 | — | -3.4% | ||
| Q2 24 | — | -5.7% | ||
| Q1 24 | -384.1% | 1.7% |
| Q4 25 | — | -5.3% | ||
| Q3 25 | -373.3% | -21.6% | ||
| Q2 25 | -229.0% | -15.9% | ||
| Q1 25 | -781.1% | -3.5% | ||
| Q4 24 | — | -4.0% | ||
| Q3 24 | — | -2.7% | ||
| Q2 24 | — | -3.0% | ||
| Q1 24 | -522.1% | -3.2% |
| Q4 25 | — | $-0.12 | ||
| Q3 25 | $-0.30 | $-0.52 | ||
| Q2 25 | $-0.18 | $-0.34 | ||
| Q1 25 | $-0.26 | $-0.06 | ||
| Q4 24 | — | — | ||
| Q3 24 | $-0.31 | $-0.07 | ||
| Q2 24 | $-0.22 | $-0.07 | ||
| Q1 24 | $-0.24 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $86.1M | — |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $265.5M | $48.1M |
| Total Assets | $661.9M | $57.8M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | — | ||
| Q3 25 | $86.1M | $41.2M | ||
| Q2 25 | $123.8M | $2.8M | ||
| Q1 25 | $95.8M | $2.0M | ||
| Q4 24 | — | $32.0K | ||
| Q3 24 | $657.1M | $262 | ||
| Q2 24 | $705.9M | $226 | ||
| Q1 24 | $758.5M | $50 |
| Q4 25 | — | $48.1M | ||
| Q3 25 | $265.5M | $50.7M | ||
| Q2 25 | $346.5M | $78.3M | ||
| Q1 25 | $371.1M | $81.8M | ||
| Q4 24 | — | $82.3M | ||
| Q3 24 | $477.0M | $82.9M | ||
| Q2 24 | $527.8M | $83.2M | ||
| Q1 24 | $582.0M | $83.6M |
| Q4 25 | — | $57.8M | ||
| Q3 25 | $661.9M | $83.6M | ||
| Q2 25 | $721.0M | $149.7M | ||
| Q1 25 | $746.3M | $152.3M | ||
| Q4 24 | — | $150.1M | ||
| Q3 24 | $827.5M | $157.3K | ||
| Q2 24 | $853.6M | $159.8K | ||
| Q1 24 | $901.4M | $170.6K |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-67.9M | $1.7M |
| Free Cash FlowOCF − Capex | $-72.3M | $1.7M |
| FCF MarginFCF / Revenue | -341.2% | 7.6% |
| Capex IntensityCapex / Revenue | 20.8% | 0.1% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-322.5M | $-16.0K |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $1.7M | ||
| Q3 25 | $-67.9M | $-4.8M | ||
| Q2 25 | $-72.8M | $2.2M | ||
| Q1 25 | $-75.6M | $1.1M | ||
| Q4 24 | — | $3.2M | ||
| Q3 24 | $-76.7M | $6.5M | ||
| Q2 24 | $-51.1M | $7.3M | ||
| Q1 24 | $-40.5M | $7.4M |
| Q4 25 | — | $1.7M | ||
| Q3 25 | $-72.3M | $-4.9M | ||
| Q2 25 | $-80.1M | $2.1M | ||
| Q1 25 | $-83.8M | $1.0M | ||
| Q4 24 | — | $2.5M | ||
| Q3 24 | $-86.3M | $6.5M | ||
| Q2 24 | $-51.9M | $7.3M | ||
| Q1 24 | $-41.0M | $6.9M |
| Q4 25 | — | 7.6% | ||
| Q3 25 | -341.2% | -18.1% | ||
| Q2 25 | -382.6% | 9.1% | ||
| Q1 25 | -933.1% | 5.0% | ||
| Q4 24 | — | 10.2% | ||
| Q3 24 | — | 21.7% | ||
| Q2 24 | — | 28.5% | ||
| Q1 24 | -406.8% | 28.1% |
| Q4 25 | — | 0.1% | ||
| Q3 25 | 20.8% | 0.4% | ||
| Q2 25 | 34.8% | 0.0% | ||
| Q1 25 | 91.8% | 0.1% | ||
| Q4 24 | — | 3.0% | ||
| Q3 24 | — | 0.0% | ||
| Q2 24 | — | 0.0% | ||
| Q1 24 | 5.3% | 2.0% |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AUTL
Segment breakdown not available.
BGSF
| Contract Field Talent | $21.4M | 97% |
| Other | $595.0K | 3% |
